Originally published as JCO Early Release 10.1200/JCO.2003.11.143 on March 13 2003

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deininger, M. W.N. Articles by Druker, B. J. Search for Related Content PubMed PubMed Citation Articles by Deininger, M. W.N. Articles by Druker, B. J. Social Bookmarking                            What's this?

Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib

Michael W.N. Deininger, Stephen G. O’Brien, John M. Ford, Brian J. Druker

From the BMT/Leukemia Center, Oregon Health and Science University Cancer Institute, Portland, OR; Department of Haematology, The Medical School, University of Newcastle, Newcastle, UK; Novartis AG, Basel, Switzerland;

Address reprint requests to Brian J. Druker, MD, Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239; email: drukerb{at}ohsu.edu.

The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML). More than 10,000 patients worldwide have been treated with imatinib in clinical trials, and a large body of information has accumulated about the use of this drug. The purpose of this article is to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions. The treatment recommendations are intended to optimize therapy with imatinib while taking into account a patient’s specific circumstances.

B.J.D. is supported by the Howard Hughes Medical Institute and by grants from the National Cancer Institute, The Leukemia and Lymphoma Society, Burroughs Wellcome Fund, T. J. Martell Foundation, and the Doris Duke Charitable Foundation.

B.J.D. and S.G.O. serve as consultants for Novartis Pharma.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Mattarucchi, O. Spinelli, A. Rambaldi, F. Pasquali, F. Lo Curto, L. Campiotti, and G. Porta Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared with Conventional mRNA Analysis J. Mol. Diagn., September 1, 2009; 11(5): 482 - 487. [Abstract] [Full Text] [PDF]

				F. Frigeri, M. Arcamone, L. Luciano, R. Di Francia, F. Pane, and A. Pinto Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia Blood, May 14, 2009; 113(20): 5028 - 5029. [Full Text] [PDF]

				S.-F. Wong Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 17 - 27. [Abstract] [PDF]

				K. Liapis, J. Apostolidis, E. Charitaki, F. Panitsas, N. Harhalakis, and E. Nikiforakis Syndrome of Inappropriate Secretion of Antidiuretic Hormone Associated with Imatinib Ann. Pharmacother., December 1, 2008; 42(12): 1882 - 1886. [Abstract] [Full Text] [PDF]

				C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg Validation of Analytic Methods for Biomarkers Used in Drug Development Clin. Cancer Res., October 1, 2008; 14(19): 5967 - 5976. [Abstract] [Full Text] [PDF]

				P. Ramirez and J. F. DiPersio Therapy Options in Imatinib Failures Oncologist, April 1, 2008; 13(4): 424 - 434. [Abstract] [Full Text] [PDF]

				C. Fausel Targeted chronic myeloid leukemia therapy: Seeking a cure Am. J. Health Syst. Pharm., December 15, 2007; 64(24_Supplement_15): S9 - S15. [Abstract] [Full Text] [PDF]

				J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF]

				Y. Ali, Y. Lin, M. M. Gharibo, M. K. Gounder, M. N. Stein, T. F. Lagattuta, M. J. Egorin, E. H. Rubin, and E. A. Poplin Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5876 - 5882. [Abstract] [Full Text] [PDF]

				C. A. Schiffer BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265. [Full Text] [PDF]

				H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Ann Intern Med, December 19, 2006; 145(12): 913 - 923. [Abstract] [Full Text] [PDF]

				D. Ferrero, E. M. Pogliani, G. Rege-Cambrin, C. Fava, G. Mattioli, C. Dellacasa, V. Giai, M. Genuardi, P. Perfetti, M. Fumagalli, et al. Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4856 - 4856. [Abstract]

				H.-P. Gschwind, U. Pfaar, F. Waldmeier, M. Zollinger, C. Sayer, P. Zbinden, M. Hayes, R. Pokorny, M. Seiberling, M. Ben-Am, et al. METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS Drug Metab. Dispos., October 1, 2005; 33(10): 1503 - 1512. [Abstract] [Full Text] [PDF]

				Z. Li, Y. Qiao, B. Liu, E. J. Laska, P. Chakravarthi, J. M. Kulko, R. D. Bona, M. Fang, U. Hegde, V. Moyo, et al. Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia Clin. Cancer Res., June 15, 2005; 11(12): 4460 - 4468. [Abstract] [Full Text] [PDF]

				P. F. Smith, J. M. Bullock, B. M. Booker, C. E. Haas, C. S. Berenson, and W. J. Jusko Induction of imatinib metabolism by hypericum perforatum Blood, August 15, 2004; 104(4): 1229 - 1230. [Full Text] [PDF]

				J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]

				R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF]

				F. Guilhot Indications for Imatinib Mesylate Therapy and Clinical Management Oncologist, June 1, 2004; 9(3): 271 - 281. [Abstract] [Full Text] [PDF]

				N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]

				K. J. Smith, E. Jacobson, S. Hamza, and H. Skelton Unexplained Hypereosinophilia and the Need for Cytogenetic and Molecular Genetic Analyses Arch Dermatol, May 1, 2004; 140(5): 584 - 588. [Abstract] [Full Text] [PDF]

				T. Tanvetyanon and S. Nand Overcoming Recurrent Cutaneous Reactions from Imatinib Using Once-Weekly Dosing Ann. Pharmacother., December 1, 2003; 37(12): 1818 - 1820. [Abstract] [Full Text] [PDF]

				A. Cashen, J. F. DiPersio, and H. Khoury Does Early Imatinib-Induced Myelosuppression Predict Hematologic Responses in Patients With Advanced-Phase Chronic Myeloid Leukemia? J. Clin. Oncol., November 15, 2003; 21(22): 4255 - 4256. [Full Text] [PDF]

				J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]